Advertisement


Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

2024 ASCO Annual Meeting

Advertisement

Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The DEB study was a phase three clinical trial that was recently presented at the ASCO meeting. This study evaluated the combination of R-CHOP with HDAC inhibitor, Tucidinostat. In this trial, it was conducted exclusively in China and it enrolled patients in the frontline setting that had double expressor lymphoma. Double expressor lymphoma is the specific subset of diffuse large B-cell lymphoma that shows increased expression of both MIC and BCL2 without the associated gene rearrangements. In this clinical trial, patients were randomized to either placebo or Tucidinostat in combination with R-CHOP, and they received that for six cycles and then went on to receive either maintenance therapy with Tucidinostat or placebo. The combination of Tucidinostat and R-CHOP in this clinical trial actually yielded increased CR rates compared to R-CHOP therapy alone, and additionally, this translated into an event-free survival benefit as well. Though there's only a short follow-up of approximately 13.9 months median at this point, and therefore we need longer followup to get a better understanding of outcomes. Importantly, this study did not show a difference in overall survival at this point. The combination of Tucidinostat and R-CHOP was relatively well tolerated, though we did see a higher incidence of hematologic toxicity along with infectious complications compared to R-CHOP therapy alone. This is overall my take on this is it's encouraging data, but we do need to have longer term followup. Additionally, questions do still remain regarding if this data is applicable to non-Asian populations, what's the impact of maintenance therapy in this clinical trial that was employed, and then, additionally, how do these results really compare to one of the other standards of care that we use in diffuse large B-cell lymphoma, which is Polatuzumab RCHP.

Related Videos

Gynecologic Cancers

Jean-Marc Classe, MD, PhD, on Ovarian Cancer: New Data on Lymphadenectomy From the CARACO Trial

Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).

Multiple Myeloma

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Lung Cancer

Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Advertisement

Advertisement




Advertisement